½ÃÀ庸°í¼­
»óǰÄÚµå
1540896

¼¼°èÀÇ µ¿¹° °¨¿°Áõ Áø´Ü ½ÃÀå º¸°í¼­ : ±â¼úº°, µ¿¹° À¯Çüº°, °¨¿° À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°(2024-2032³â)

Veterinary Infectious Disease Diagnostics Market Report by Technology, Animal Type, Infection Type, End User, and Region 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 141 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è µ¿¹° °¨¿°Áõ Áø´Ü ½ÃÀå ±Ô¸ð´Â 2023³â 20¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2032³â±îÁö ½ÃÀå ±Ô¸ð°¡ 40¾ï ´Þ·¯¿¡ ´ÞÇϰí, 2024-2032³â°£ 7.4%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖ½À´Ï´Ù. ¹Ý·Áµ¿¹°°ú °¡ÃàÀÇ Áúº´ È®»ê, º¸È£ÀÚÀÇ ÀÎ½Ä Áõ°¡, ±â¼ú ¹ßÀü, Á¤È®ÇÑ Áø´ÜÀÇ Çʿ伺, ÷´Ü µµ±¸ÀÇ Ã¤ÅÃ, ¹Ý·Áµ¿¹° °Ç°­¿¡ ´ëÇÑ °ü½É Áõ°¡, ¼öÀÇÇÐ ÀÎÇÁ¶ó È®´ë, Àμö°øÅëÀü¿°º´ ¿¹¹æÀ» À§ÇÑ Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê, ¿¬±¸ ÀÚ±Ý Áö¿ø °­È­ µîÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀ¸·Î ²ÅÈü´Ï´Ù.

µ¿¹° °¨¿°Áõ Áø´Ü ½ÃÀå ºÐ¼® :

ÁÖ¿ä ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ Àü ¼¼°èÀûÀ¸·Î Àμö°øÅëÀü¿°º´ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÷´Ü Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖ¾î ½ÃÀå Àü¸ÁÀÌ ¹à½À´Ï´Ù. ¶ÇÇÑ, µ¿¹° ÀÇ·á¿¡ ´ëÇÑ Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê¿Í ÀÚ±Ý Áö¿ø Áõ°¡´Â µ¿¹° °¨¿°Áõ Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ãà»ê »ê¾÷ÀÇ È®´ë¿Í ÁÖ¿ä ±â¾÷µéÀÇ ¿¬±¸°³¹ß(R&D) Ȱµ¿ Áõ°¡µµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇöÀå Áø·á(POC) Áø´ÜÀÇ »ç¿ë È®´ë, ¼öÀÇÇÐ ºÐ¾ß¿¡¼­ ¿ø°Ý ÀÇ·áÀÇ ±Þ°ÝÇÑ Áõ°¡, µ¿¹° º¹Áö ¹× ǰÁú ±âÁØ¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ¼öÀÇÇÐ °¨¿°Áõ Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå µ¿Çâ : ¿ì¼öÇÑ ¹Î°¨µµ¿Í ƯÀ̼ºÀ¸·Î ÀÎÇØ ºÐÀÚÁø´Ü¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁø °ÍÀÌ ÁÖ¿ä ½ÃÀå µ¿Çâ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ, CRISPR(clustered regularly interspaced short palindromic repeats)Àº ÇöÀå¿¡¼­ Á¶ÀÛÀÌ °¡´ÉÇϱ⠶§¹®¿¡ Áø´Ü¿¡ ´ëÇÑ È°¿ëÀÌ ±ÞÁõÇϰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀΰøÁö´É(AI)°ú ¸Ó½Å·¯´×(ML)ÀÇ ÅëÇÕÀÌ ÁøÇàµÇ¸é¼­ ƯÈ÷ Áø´Ü µµ±¸¿¡¼­ º¸´Ù Á¤È®ÇÑ °á°ú¸¦ ¾òÀ» ¼ö ÀÖ°Ô µÈ °Íµµ µ¿¹° °¨¿°Áõ Áø´Ü ½ÃÀåÀÇ ±àÁ¤ÀûÀÎ Àü¸ÁÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²² ¹Ý·Áµ¿¹°¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ´Ù¾çÇÑ º´¿øÃ¼¸¦ µ¿½Ã¿¡ °ËÃâÇÏ´Â ¸ÖƼÇ÷º½º Áø´Ü¹ýÀ¸·ÎÀÇ Á¡ÁøÀûÀÎ ÀüȯÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, µ¿¹°º´¿ø°ú Áø´Ü ½ÇÇè½ÇÀÇ Çù·Â°ú ÇöÀåÁø´Ü(POC) Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϸ鼭 ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

Áö¸®Àû µ¿Çâ : µ¿¹° °¨¿°Áõ Áø´Ü ½ÃÀå ¿¹Ãø¿¡ µû¸£¸é, ºÏ¹Ì´Â ÷´Ü ÀÇ·á ÀÎÇÁ¶óÀÇ Á¸Àç, ¹Ý·Áµ¿¹° »çÀ°µÎ¼ö Áõ°¡, µ¿¹° °Ç°­¿¡ ´ëÇÑ ÅõÀÚ ±ÞÁõÀ¸·Î ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä ±â¾÷µéÀÇ ¿¬±¸°³¹ß(R&D)¿¡ ´ëÇÑ ÁýÁßÀûÀÎ ³ë·Â°ú Á¤ºÎÀÇ ¿ìÈ£ÀûÀÎ Á¤Ã¥ÀÌ ÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. À¯·´Àº ¾ö°ÝÇÑ µ¿¹° À§»ý ±ÔÁ¦¿Í ´Ù¼öÀÇ ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷µéÀÌ Á¸ÀçÇÏ¿© ½ÃÀå¿¡¼­ »ó´çÇÑ Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­´Â µ¿¹° À§»ý¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, °¨¿°¼º Áø´ÜÀÇ ¿ëÀ̼º, µ¿¹° À§»ý¿¡ ´ëÇÑ Á¤ºÎ ÀÚ±ÝÀÇ ±Þ°ÝÇÑ Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

°æÀï»óȲ: µ¿¹° °¨¿°Áõ Áø´Ü »ê¾÷ÀÇ ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷À¸·Î´Â Abbott Laboratories, Biomerieux SA, Creative Diagnostics, HESKA Corporation, Innovative Diagnostics, IDEXX Laboratories Inc., Neogen Corporation, Qiagen N.V., Randox Laboratories Ltd, Thermo Fisher Scientific Inc. µîÀÌ ÀÖ½À´Ï´Ù.

°úÁ¦ ¹× ±âȸ: µ¿¹° °¨¿°Áõ Áø´Ü ½ÃÀå º¸°í¼­¿¡ µû¸£¸é, Áø´Ü µµ±¸ÀÇ ºñ¿ë »ó½ÂÀº ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ, ±ÔÁ¦ À庮°ú º¹ÀâÇÑ ½ÂÀÎ ÀýÂ÷·Î ÀÎÇØ ½ÃÀå ÁøÃâ±â¾÷µé¿¡°Ô ´Ù¾çÇÑ µµÀü°úÁ¦¸¦ ¾ß±âÇϰí ÀÖÀ¸¸ç, ÀÌ ¶ÇÇÑ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª µ¿¹°ÀÇ °¨¿°ÁõÀÇ À¯Çà°ú ¹Ý·Áµ¿¹° »çÀ° ¼ö Áõ°¡·Î ÀÎÇØ °í±Þ Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡ÇÏ´Â µî ½ÃÀå¿¡´Â ´Ù¾çÇÑ ±âȸ°¡ âÃâµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Æí¸®ÇÏ°í »ç¿ëÇϱ⠽¬¿î Áø´Ü ±â±âÀÇ ÃâÇöÀ» Æ÷ÇÔÇÑ ±â¼úÀÇ ±Þ¼ÓÇÑ ¹ßÀü°ú ¼öÀÇ»çÀÇ °Ç°­°ú º¹Áö¿¡ ´ëÇÑ °ü½É Áõ°¡´Â µ¿¹° °¨¿°Áõ Áø´Ü ½ÃÀåÀÇ ¼öÀÍÀ» Å©°Ô Áõ°¡½ÃŰ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

µ¿¹° °¨¿°Áõ Áø´Ü ½ÃÀå µ¿Çâ :

¹Ý·Áµ¿¹°°ú °¡ÃàÀÇ °¨¿°º´ È®»ê

¹Ý·Áµ¿¹°°ú °¡ÃàÀÇ °¨¿°ÁõÀÌ Áõ°¡Çϸ鼭 ½ÃÀå ¼ºÀå¿¡ °¡¼Óµµ°¡ ºÙ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, °í¾çÀÌ ¹éÇ÷º´ ¹ÙÀÌ·¯½º(FeLV)´Â °í¾çÀÌÀÇ °¡Àå ÈçÇÑ Àü¿°º´ Áß ÇϳªÀ̸ç, ¹Ì±¹°ú ij³ª´Ù¿¡¼­´Â °í¾çÀÌÀÇ 2-3%°¡ ÀÌ Áúº´¿¡ °É¸³´Ï´Ù. ÀÌ·¯ÇÑ À§ÇèÀº ¹Ý·Áµ¿¹°°ú Àΰ£ °£ÀÇ »óÈ£ ÀÛ¿ëÀÌ ±ÞÁõÇÔ¿¡ µû¶ó ´õ¿í ÁõÆøµÇ¾î Áúº´ °¨¿°ÀÇ °¡´É¼ºÀ» ´õ¿í È®´ë½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±Þ¼ÓÇÑ µµ½ÃÈ­, µ¿¹° »çÀ° ¹æ½ÄÀÇ º¯È­, Áø´Ü ȯÀÚ ¼ö Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. µ¿¹° Àü¿°º´ Áø´Ü ½ÃÀåÀÇ °¡Ä¡¸¦ ³ôÀÌ´Â ¶Ç ´Ù¸¥ ¿äÀÎÀº ÀÌ·¯ÇÑ Áúº´ÀÇ È¿À²ÀûÀÎ ÅëÁ¦¿Í ºÀ¼â¸¦ Áö¿øÇÒ ¼ö ÀÖ´Â Á¤È®ÇÏ°í ½Ã±âÀûÀýÇÑ Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù.

¹Ý·Áµ¿¹° º¸È£ÀÚÀÇ ÀÇ½Ä Çâ»ó

Áúº´ Á¶±â ¹ß°ßÀÇ Á߿伺¿¡ ´ëÇÑ º¸È£ÀÚµéÀÇ ÀνÄÀÌ ³ô¾ÆÁö´Â °ÍÀº ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â Áß¿äÇÑ ¿äÀÎÀÔ´Ï´Ù. ¹Ý·Áµ¿¹°Àº ÇʼöÀûÀÎ °¡Á· ±¸¼º¿øÀ¸·Î °£ÁֵDZ⠶§¹®¿¡ ¹Ý·Áµ¿¹°ÀÇ °Ç°­°ú ÇູÀ» ¿ì¼±¼øÀ§¿¡ µÎ´Â º¸È£ÀÚ°¡ Á¡Á¡ ´õ ¸¹¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÎ½Ä Áõ°¡´Â Á¤±âÀûÀÎ °Ç°­ °ËÁø, ¿¹¹æ Á¶Ä¡ ¹× Á¶±â Áø´Ü °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÷´Ü Áø´Ü µµ±¸¿Í ±â¼úÀÇ ¹ß´Þ·Î ¹Ý·Áµ¿¹° º¸È£ÀÚµéÀÌ ¾çÁúÀÇ ¼öÀÇÇÐÀû Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖ°Ô µÇ¸é¼­ °¨¿°Áõ Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀü

½ÃÀå °³¿ä¿¡ µû¸£¸é, µ¿¹° °¨¿°Áõ Áø´ÜÀº ±Þ¼ÓÇÑ ±â¼ú ¹ßÀüÀ¸·Î ÀÎÇØ »ó´çÇÑ ¼ö¿ä¸¦ º¸À̰í ÀÖ½À´Ï´Ù. Áø´ÜÀÇ °³¼±À¸·Î Áø´Ü °á°úÀÇ È¿À²¼º°ú Á¤È®¼ºÀÌ Å©°Ô Çâ»óµÇ¾î ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁßÇÕ È¿¼Ò ¿¬¼â¹ÝÀÀ(PCR)°ú °°Àº µ¿¹° Àü¿°º´ÀÇ Å½Áö ¹× ½Äº°À» °³¼±Çϱâ À§ÇØ °í¾ÈµÈ ºÐÀÚÁø´Ü ±â¼úÀÇ µµÀÔÀº ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î ÀÚµ¿ ºÐ¼®±â ¹× ¿ø°Ý ÀÇ·á Ç÷§Æû°ú °°Àº µðÁöÅÐ °Ç°­ µµ±¸ÀÇ µµÀÔÀ¸·Î Áø´Ü ÇÁ·Î¼¼½º°¡ °£¼ÒÈ­µÇ¾î ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

µ¿¹° °¨¿°Áõ Áø´Ü ½ÃÀå ¼¼ºÐÈ­ :

IMARC GroupÀº °¢ ½ÃÀå ºÎ¹®ÀÇ ÁÖ¿ä µ¿Ç⠺м®°ú 2024-2032³â±îÁöÀÇ ¼¼°è, Áö¿ª ¹× ±¹°¡º° ¿¹ÃøÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ º¸°í¼­´Â ±â¼ú, µ¿¹° À¯Çü, °¨¿° À¯Çü ¹× ÃÖÁ¾ »ç¿ëÀÚ¸¦ ±âÁØÀ¸·Î ½ÃÀåÀ» ºÐ·ùÇÕ´Ï´Ù.

±â¼úº° ºÐ¼®

¸é¿ª Áø´ÜÀÌ ½ÃÀå Á¡À¯À²ÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÕ´Ï´Ù.

ÀÌ º¸°í¼­´Â ±â¼úº°·Î ½ÃÀåÀ» ¼¼ºÎÀûÀ¸·Î ºÐ·ùÇÏ°í ºÐ¼®ÇÕ´Ï´Ù. ¿©±â¿¡´Â ¸é¿ªÁø´Ü, ºÐÀÚÁø´Ü, ±âŸ µîÀÌ Æ÷ÇԵ˴ϴÙ. º¸°í¼­¿¡ µû¸£¸é, ¸é¿ªÁø´ÜÀÌ °¡Àå Å« ºÎºÐÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­ º¸°í¼­¿¡ µû¸£¸é, Á¤È®ÇÑ Áúº´ °ËÃâ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ¸é¿ªÁø´ÜÇÐ ºÎ¹®ÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. È¿¼Ò °áÇÕ ¸é¿ª ÈíÂø ºÐ¼®¹ý(ELISA) ¹× ¸é¿ª Çü±¤ ºÐ¼®¹ý(IFA)À» Æ÷ÇÔÇÑ ¸é¿ª Áø´Ü Å×½ºÆ®´Â °¨¿°°ú °ü·ÃµÈ Ç×ü ¹× Ç׿øÀ» ƯÀÌÀûÀ¸·Î °ËÃâÇÏ´Â ´É·ÂÀÌ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Á¤È®¼ºÀº º´¿øÃ¼¸¦ ½Äº°Çϰí Áúº´À» Á¶±â¿¡ Áø´ÜÇÏ¿© È¿°úÀûÀÎ Ä¡·á¿Í Áúº´ °ü¸®¿¡ ÇʼöÀûÀÎ Áúº´À» Á¶±â¿¡ Áø´ÜÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¼öÀÇÇÐÀÌ °íµµÈ­µÊ¿¡ µû¶ó, ¼öÀÇ»çµéÀº ½Å¼ÓÇÑ Áø´Ü °á°ú¸¦ Á¦°øÇÒ ¼ö ÀÖ´Â ½Å·ÚÇÒ ¼ö ÀÖ´Â Áø´Ü µµ±¸¿¡ ´ëÇÑ ±â´ë°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¹Ý·Áµ¿¹°°ú °¡ÃàÀÇ °¨¿°ÁõÀÇ È®»êÀÌ ½É°¢ÇØÁü¿¡ µû¶ó ÀÌ·¯ÇÑ Á¤È®ÇÑ Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ Çʿ伺ÀÌ ´õ¿í Ä¿Áö°í ÀÖ½À´Ï´Ù.

µ¿¹° À¯Çüº° ºÐ¼®

¹Ý·Áµ¿¹°ÀÌ ¾÷°è ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

º¸°í¼­¿¡´Â µ¿¹° À¯Çüº° ½ÃÀå ¼¼ºÐÈ­ ¹× ºÐ¼®µµ »ó¼¼ÇÏ°Ô Á¦½ÃµÇ¾î ÀÖ½À´Ï´Ù. ¿©±â¿¡´Â ¹Ý·Áµ¿¹°°ú ½Äǰ »ý»ê µ¿¹°ÀÌ Æ÷ÇԵ˴ϴÙ. º¸°í¼­¿¡ µû¸£¸é ¹Ý·Áµ¿¹°ÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

µ¿¹° °¨¿° Áø´Ü ½ÃÀåÀÇ ¹Ý·Áµ¿¹° ºÎ¹®Àº ¹Ý·Áµ¿¹°ÀÇ °Ç°­°ú À£ºù¿¡ ´ëÇÑ °ü½É, Áø´Ü ±â¼úÀÇ ¹ßÀü¿¡ ÈûÀÔ¾î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹Ý·Áµ¿¹° º¸È£ÀÚµéÀÌ Áúº´ÀÇ Á¶±â ¹ß°ßÀ» ¿ì¼±½ÃÇϰí Àû±ØÀûÀÎ °Ç°­ °ü¸®ÀÇ ÀÌÁ¡À» ÀνÄÇÏ°Ô µÈ °Íµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÎ½Ä Áõ°¡´Â Áúº´ÀÌ ½É°¢ÇØÁö±â Àü¿¡ Áúº´À» ½Äº°ÇÒ ¼ö ÀÖ´Â Áø´Ü ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½ÃÄÑ ¹Ý·Áµ¿¹°ÀÇ °Ç°­ »óŸ¦ °³¼±ÇÏ´Â µ¥ µµ¿òÀÌ µÉ °ÍÀÔ´Ï´Ù. ºÐÀÚ ºÐ¼® ¹× ½Å¼ÓÇÑ ÇöÀå °Ë»ç µî Á¤È®ÇÏ°í ½Ã±âÀûÀýÇÑ °á°ú¸¦ Á¦°øÇϴ ÷´Ü Áø´Ü µµ±¸ÀÇ Ãâ½Ãµµ ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ¼öÀǻ簡 °¨¿°ÁõÀ» º¸´Ù È¿°úÀûÀ¸·Î Áø´ÜÇϰí Ä¡·áÇÒ ¼ö ÀÖ°Ô ÇÔÀ¸·Î½á ¹Ý·Áµ¿¹°ÀÇ Àü¹ÝÀûÀÎ Ä¡·á ǰÁúÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù.

°¨¿°º´ À¯Çüº° ºÐ·ù :

¹ÚÅ׸®¾Æ °¨¿°ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ºÎ¹®À» Â÷ÁöÇÕ´Ï´Ù.

ÀÌ º¸°í¼­´Â °¨¿° À¯Çüº°·Î ½ÃÀåÀ» ¼¼ºÎÀûÀ¸·Î ºÐ·ùÇÏ°í ºÐ¼®ÇÕ´Ï´Ù. ¿©±â¿¡´Â ¼¼±Õ °¨¿°, ¹ÙÀÌ·¯½º °¨¿°, ±â»ýÃæ °¨¿°, ±âŸ µîÀÌ Æ÷ÇԵ˴ϴÙ. º¸°í¼­¿¡ µû¸£¸é ¼¼±Õ °¨¿°ÀÌ °¡Àå Å« ºÎºÐÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

µ¿¹° °¨¿° Áø´Ü ½ÃÀåÀÇ ¼¼±Õ¼º °¨¿° ºÎ¹®Àº È¿°úÀûÀÎ °ü¸® ¹× ÅëÁ¦¸¦ À§ÇÑ Ã·´Ü Áø´Ü µµ±¸°¡ ÇÊ¿äÇÑ µ¿¹°µé »çÀÌ¿¡¼­ ¼¼±Õ¼º ÁúȯÀÇ ±ÞÁõÇÏ´Â À¯º´·ü¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¹Ý·Áµ¿¹°°ú °¡Ãà ¸ðµÎ ·¾Å佺ÇǶóÁõ, °áÇÙ, »ì¸ð³Ú¶ó µî ¼¼±Õ¼º °¨¿°ÁõÀÇ ¹ß»ý·üÀÌ Áõ°¡Çϸ鼭 Á¤¹Ð Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¼¼±Õ¼º Áúº´ÀÌ µ¿¹°ÀÇ °Ç°­°ú »ý»ê¼º¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ Á¶±â ¹ß°ß°ú °³ÀÔÀ» º¸ÀåÇϱâ À§ÇÑ °ß°íÇÑ Áø´Ü ¹æ¹ýÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °¡ÃàÀÇ ¼¼±Õ °¨¿°ÀÌ ½Äǰ °ø±ÞÀ» ¿À¿°½Ãų ¼ö ÀÖ¾î ¾ö°ÝÇÑ °Ë»ç ¹× ¸ð´ÏÅ͸µ ¿ä°ÇÀÌ ¿ä±¸µÊ¿¡ µû¶ó ÀÌ ºÎ¹®Àº ½Äǰ ¾ÈÀü¿¡ ´ëÇÑ ÃÊÁ¡ÀÌ À̵¿ÇÏ´Â ¹è°æÀÌ µÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ ½ÅÈï±¹¿¡¼­ ¼öÀÇÇÐ ÀÎÇÁ¶ó ¹× ¼­ºñ½º È®´ë´Â Áø´Ü ±â¼ú¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» °­È­ÇÔÀ¸·Î½á ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚº° ºÐ¼®

Ç¥ÁØ ½ÃÇè½ÇÀº ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÃÖÁ¾ »ç¿ëÀÚº°·Î ½ÃÀåÀ» ¼¼ºÎÀûÀ¸·Î ºÐ·ùÇÏ°í ºÐ¼®ÇÕ´Ï´Ù. ¿©±â¿¡´Â Ç¥ÁØ ½ÇÇè½Ç, µ¿¹° ½ÇÇè½Ç ¹× Ŭ¸®´Ð, POC/º´¿ø ³» Å×½ºÆ®, ¿¬±¸±â°ü ¹× ´ëÇÐÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ º¸°í¼­¿¡ µû¸£¸é, ±âÁØ ½ÇÇè½ÇÀÌ °¡Àå Å« ºÎ¹®À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

µ¿¹° °¨¿°Áõ Áø´Ü ½ÃÀåÀÇ ÂüÁ¶ ½ÇÇè½Ç ºÎ¹®Àº Áø´Ü Å×½ºÆ® ¿ä°ÇÀÇ º¹À⼺ Áõ°¡·Î ÀÎÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¼öÀÇ Áø´ÜÀÌ °íµµÈ­µÊ¿¡ µû¶ó, ÂüÁ¶ ½ÇÇè½ÇÀº °íµµÀÇ ¿ª·®°ú Àü¹®¼ºÀ» ¹ÙÅÁÀ¸·Î Á¡Á¡ ´õ ¸¹Àº ½Å·Ú¸¦ ¹Þ°í ÀÖ½À´Ï´Ù. ÀÌ ºÎ¹®Àº ´Ù¾çÇÑ º´¿øÃ¼¿Í Áúº´À» ±¸º°ÇÒ ¼ö ÀÖ´Â Á¤È®Çϰí Á¾ÇÕÀûÀÎ Áø´Ü Å×½ºÆ®¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹À⼺ ¶§¹®¿¡ °íµµ·Î Àü¹®È­µÈ Àåºñ¿Í ¼÷·ÃµÈ ÀηÂÀÇ »ç¿ëÀÌ ÇÊ¿äÇϸç, À̴ ǥÁØ ½ÇÇè½ÇÀÇ Æ¯Â¡ÀÔ´Ï´Ù. ¶Ç ´Ù¸¥ ÀåÁ¡À¸·Î´Â öÀúÇÑ °íÇØ»óµµ ºÐ¼®ÀÌ ÇÊ¿äÇÑ Áø´Ü¿ë »ùÇÃÀÇ ¾çÀÌ Áõ°¡Çϰí ÀÖ´Ù´Â Á¡À» µé ¼ö ÀÖ½À´Ï´Ù. ºÐÀÚÁø´Ü ¹× À¯Àüü ºÐ¼®°ú °°Àº °í±Þ °Ë»ç¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌ·¯ÇÑ °Ë»ç¸¦ Á¤¹ÐÇÏ°Ô ¼öÇàÇÒ ¼ö ÀÖ´Â Àü¹® Ç¥ÁØ °Ë»ç±â°ü¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

Áö¿ªº° ºÐ¼®

ºÏ¹Ì°¡ ½ÃÀåÀ» ¼±µµÇÏ¸ç °¡Àå Å« µ¿¹° °¨¿°Áõ Áø´Ü ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ºÏ¹Ì(¹Ì±¹, ij³ª´Ù), ¾Æ½Ã¾ÆÅÂÆò¾ç(Áß±¹, ÀϺ», Àεµ, Çѱ¹, È£ÁÖ, Àεµ³×½Ã¾Æ, ±âŸ), À¯·´(µ¶ÀÏ, ÇÁ¶û½º, ¿µ±¹, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ·¯½Ã¾Æ, ±âŸ), ¶óƾ¾Æ¸Þ¸®Ä«(ºê¶óÁú, ¸ß½ÃÄÚ, ±âŸ), Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« µî ÁÖ¿ä Áö¿ª ½ÃÀåÀ» Á¾ÇÕÀûÀ¸·Î ºÐ¼®ÇÕ´Ï´Ù. ÁÖ¿ä Áö¿ª ½ÃÀåµµ Á¾ÇÕÀûÀ¸·Î ºÐ¼®Çß½À´Ï´Ù. º¸°í¼­¿¡ µû¸£¸é ºÏ¹Ì´Â µ¿¹°¿ë Àü¿°º´ Áø´ÜÀÇ °¡Àå ±Ô¸ð°¡ Å« Áö¿ª ½ÃÀåÀÔ´Ï´Ù.

ºÏ¹Ì µ¿¹° °¨¿°Áõ Áø´Ü ½ÃÀåÀº ¹Ý·Áµ¿¹°°ú °¡ÃàÀÇ °¨¿°ÁõÀÌ È®»êµÇ°í ÀÖ½À´Ï´Ù. °³ µð½ºÅÛÆÛ, °í¾çÀÌ ¹éÇ÷º´, °¢Á¾ Àμö°øÅëÀü¿°º´ µîÀÇ ¹ßº´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó È¿°úÀûÀÎ Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ª ½ÃÀåÀº Áúº´ Á¶±â ¹ß°ß°ú ¿¹¹æÀÇ Á߿伺¿¡ ´ëÇÑ ¹Ý·Áµ¿¹° º¸È£ÀÚµéÀÇ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ½ÃÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ºÏ¹Ì ¹Ý·Áµ¿¹° º¸È£ÀÚµéÀº ¹Ý·Áµ¿¹°ÀÇ °Ç°­¿¡ ´ëÇØ ´õ ¸¹Àº Á¤º¸¸¦ ¾ò°í Àû±ØÀûÀ¸·Î ÇൿÇϰí ÀÖÀ¸¸ç, ÀÌ´Â °í±Þ Áø´Ü ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºÐÀÚ»ý¹°ÇÐ, ½Å¼Ó °Ë»ç¹ý, ÀÚµ¿ ºÐ¼® ÀåºñÀÇ Çõ½Å µî ¼öÀÇ Áø´Ü ºÐ¾ßÀÇ ±â¼ú ¹ßÀüÀÌ °¡¼ÓÈ­µÇ¸é¼­ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº Áø´Ü ÇÁ·Î¼¼½ºÀÇ Á¤È®¼º, ¼Óµµ, È¿À²¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î, ¼öÀÇÇÐ ¿¬±¸ ¹× °³¹ß(R&D)¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ °ø°ø ¹× ¹Î°£ ºÎ¹®ÀÇ ¸·´ëÇÑ ÅõÀÚ°¡ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

°æÀï»óȲ :

ÀÌ ½ÃÀå Á¶»ç º¸°í¼­´Â ½ÃÀå °æÀï ±¸µµ¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®µµ Á¦°øÇÕ´Ï´Ù. ¸ðµç ÁÖ¿ä ±â¾÷ÀÇ »ó¼¼ÇÑ ÇÁ·ÎÆÄÀϵµ Á¦°øÇÕ´Ï´Ù. µ¿¹° °¨¿°Áõ Áø´Ü »ê¾÷ÀÇ ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷À¸·Î´Â Abbott Laboratories, Biomerieux SA, Creative Diagnostics, HESKA Corporation, Innovative Diagnostics, IDEXX Laboratories Inc., Neogen Corporation, Qiagen N.V., Randox Laboratories Ltd, Thermo Fisher Scientific Inc. µîÀÌ ÀÖ½À´Ï´Ù.

(ÀÌ ¸ñ·ÏÀº ÁÖ¿ä ÁøÃâ ±â¾÷ÀÇ ÀϺΠ¸ñ·ÏÀ̸ç, Àüü ¸ñ·ÏÀº º¸°í¼­¿¡¼­ È®ÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù).

½ÃÀåÀÇ ÁÖ¿ä µ¿¹° °¨¿° Áø´Ü ±â¾÷ Áß ÀϺδ °æÀï·ÂÀ» À¯ÁöÇÏ°í ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϱâ À§ÇØ ¸î °¡Áö Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê¿¡ Àû±ØÀûÀ¸·Î Âü¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌµé ±â¾÷Àº Áø´Ü ±â¼úÀÇ Çõ½Å°ú °­È­¸¦ À§ÇØ ±¤¹üÀ§ÇÑ ¿¬±¸°³¹ß¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. R&D¿¡ ¸¹Àº ÅõÀÚ¸¦ ÅëÇØ ºÐÀÚ ºÐ¼® ¹× ½Å¼Ó °Ë»ç Àåºñ¿Í °°Àº ÷´Ü Áø´Ü µµ±¸¸¦ µµÀÔÇÏ¿© °¨¿°ÁõÀ» º¸´Ù Á¤È®ÇÏ°í ºü¸£°Ô °¨ÁöÇÒ ¼ö ÀÖµµ·Ï ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ¿¬±¸ ±â°ü ¹× Çмú ´Üü¿ÍÀÇ Çù·Âµµ ¿ì¼±¼øÀ§¿¡ µÎ¾î ÃÖ÷´Ü ±â¼ú ¹× ¼Ö·ç¼Ç °³¹ßÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌµé ±â¾÷Àº Àü·«Àû Àμö ¹× Á¦ÈÞ¸¦ ÅëÇØ Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ È®ÀåÇÏ¿© º¸´Ù ±¤¹üÀ§ÇÑ Áø´Ü ¼Ö·ç¼ÇÀ» Á¦°øÇÏ°í »õ·Î¿î ½ÃÀå¿¡ ÁøÀÔÇÒ ¼ö ÀÖµµ·Ï Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °íǰÁú Áø´Ü Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ Á¦Á¶ ¿ª·®À» °­È­Çϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ±â¾÷µéÀº µðÁöÅÐ ±â¼ú°ú µ¥ÀÌÅÍ ºÐ¼®À» ÅëÇØ Áø´Ü ÇÁ·Î¼¼½º¸¦ °³¼±ÇÏ°í ½Ç½Ã°£ °á°ú¿Í ¿¹ÃøÀû ÅëÂû·ÂÀ» Á¦°øÇÏ´Â ÅëÇÕ ¼Ö·ç¼ÇÀ» Á¦°øÇϱâ À§ÇØ µðÁöÅÐ ±â¼úÀ» µµÀÔÇϰí ÀÖ½À´Ï´Ù.

µ¿¹° °¨¿°Áõ Áø´Ü ½ÃÀå ´º½º :

2023³â IDEXX Laboratories´Â °³¿Í °í¾çÀÌÀÇ ½ÅÀå ¼Õ»óÀ» °¨ÁöÇÏ´Â ¼±±¸ÀûÀÎ µ¿¹°¿ë Áø´Ü Å×½ºÆ®¸¦ ¹ßÇ¥Çß½À´Ï´Ù. IDEXX´Â µ¿¹° ÀÇ·á ºÐ¾ßÀÇ ¹ÌÃæÁ· ¼ö¿ä¸¦ ÃæÁ·½Ãų ¼ö Àִ ÷´Ü Áø´Ü ¼Ö·ç¼ÇÀ¸·Î Æ÷Æ®Æú¸®¿À¸¦ È®ÀåÇÏ´Â Àü·«ÀÇ ÀÏȯÀ¸·Î, ÀÌ ½ÃÇèÀº µ¿Á¾ ¾÷°è ÃÖÃÊÀÇ ½ÃÇèÀÔ´Ï´Ù. ÀÌ »õ·Î¿î ½ÃÇèÀº ¹Ý·Áµ¿¹°ÀÇ Á¶±â Áø´Ü°ú Ä¡·á °á°ú¸¦ Å©°Ô Çâ»ó½ÃÄÑ ¹Ý·Áµ¿¹°ÀÇ »îÀÇ ÁúÀ» °³¼±ÇÏ°í ¼ö¸íÀ» ¿¬ÀåÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

2023³â Mars´Â HESKA CorporationÀ» ÀμöÇϰí HESKA¸¦ Mars PetCareÀÇ R&D ºÎ¹®¿¡ ÅëÇÕÇÏ¿© ÷´Ü Áø´Ü ±â¼ú¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» Å©°Ô È®ÀåÇϰí R&D ÀÌ´Ï¼ÅÆ¼ºê¸¦ °¡¼ÓÈ­ÇÒ ¿¹Á¤ÀÔ´Ï´Ù. À̹ø Àμö¸¦ ÅëÇØ HESKA´Â POC(Point-of-Care) Áø´Ü, ¿ø°Ý ÀÇ·á ¹× Çõ½ÅÀûÀÎ ±â¼úÀ» Æ÷ÇÔÇÑ Á¾ÇÕÀûÀÎ Áø´Ü ¼Ö·ç¼ÇÀ» Àü ¼¼°è ¼öÀÇ»çµé¿¡°Ô Á¦°øÇÒ ¼ö ÀÖ´Â ¿ª·®À» °­È­ÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëÇϰí ÀÖ½À´Ï´Ù.

2024³â, Neogen CorporationÀº SureKill Gel Bait Pro Applicator¸¦ µµÀÔÇÏ¿© Á¦Ç° ¶óÀÎÀ» È®ÀåÇßÀ¸¸ç, SureKill Á¦Ç° ¶óÀο¡ »õ·Ó°Ô Ãß°¡µÈ ÀÌ Á¦Ç°Àº ƯÈ÷ µ¿¹° °Ç°­ÀÌ ¿ì¼±½ÃµÇ´Â ȯ°æ¿¡¼­ ÇØÃæ ¹æÁ¦ ¼Ö·ç¼ÇÀ» °­È­ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. °­È­ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ÀÌ ¾îÇø®ÄÉÀÌÅÍ´Â È¿À²ÀûÀ̰í È¿°úÀûÀÎ ÇØÃæ ¹æÁ¦¸¦ Á¦°øÇÏ¿© °¡Ãà°ú ¹Ý·Áµ¿¹°¿¡°Ô º¸´Ù ¾ÈÀüÇÏ°í °Ç°­ÇÑ È¯°æÀ» º¸ÀåÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®µé

  • ¼¼°è µ¿¹° °¨¿°Áõ Áø´Ü ½ÃÀåÀº Áö±Ý±îÁö ¾î¶»°Ô ¼ºÀåÇØ ¿ÔÀ»±î?
  • µ¿¹° °¨¿°Áõ Áø´Ü ½ÃÀå ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ ¹× ±âȸ´Â ¹«¾ùÀΰ¡?
  • °¢ µ¿ÀÎ, ¾ïÁ¦¿äÀÎ ¹× ±âȸ°¡ ¼¼°è µ¿¹° °¨¿°Áõ Áø´Ü ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀº?
  • ÁÖ¿ä Áö¿ª ½ÃÀåÀº?
  • °¡Àå ¸Å·ÂÀûÀÎ µ¿¹°¿ë Àü¿°º´ Áø´Ü ½ÃÀåÀº ¾î´À ±¹°¡Àΰ¡?
  • ±â¼úº° ½ÃÀå ÇöȲÀº?
  • µ¿¹° °¨¿°Áõ Áø´Ü ½ÃÀå¿¡¼­ °¡Àå ¸Å·ÂÀûÀÎ ±â¼úÀº?
  • µ¿¹° À¯Çüº° ½ÃÀå ºÐ¼®Àº?
  • µ¿¹°¿ë Àü¿°º´ Áø´Ü ½ÃÀå¿¡¼­ °¡Àå ¸Å·ÂÀûÀÎ µ¿¹° Á¾Àº?
  • °¨¿° À¯Çüº° ½ÃÀå ÇöȲÀº?
  • µ¿¹° °¨¿°Áõ Áø´Ü ½ÃÀå¿¡¼­ °¡Àå ¸Å·ÂÀûÀÎ °¨¿°º´ À¯ÇüÀº?
  • ÃÖÁ¾»ç¿ëÀÚº° ½ÃÀå ºÐ¼®Àº?
  • µ¿¹° °¨¿°Áõ Áø´Ü ½ÃÀå¿¡¼­ °¡Àå ¸Å·ÂÀûÀÎ ÃÖÁ¾ »ç¿ëÀÚ´Â?
  • ½ÃÀå °æÀï ±¸µµ´Â?
  • ¼¼°è µ¿¹° °¨¿°Áõ Áø´Ü ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷Àº?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • º¸ÅÒ¾÷ Á¢±Ù
    • Åé´Ù¿î Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼­·Ð

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ µ¿¹° °¨¿°Áõ Áø´Ü ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ºÐ¼®
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ºÐ¼® : ±â¼úº°

  • ¸é¿ªÁø´Ü
  • ºÐÀÚÁø´Ü
  • ±âŸ

Á¦7Àå ½ÃÀå ºÐ¼® : µ¿¹° À¯Çüº°

  • ¹Ý·Áµ¿¹°
  • ½Ä¿ë µ¿¹°

Á¦8Àå ½ÃÀå ºÐ¼® : °¨¿° À¯Çüº°

  • ¼¼±Õ °¨¿°
  • ¹ÙÀÌ·¯½º °¨¿°
  • ±â»ýÃæ °¨¿°
  • ±âŸ

Á¦9Àå ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

  • ÂüÁ¶ ½ÇÇè½Ç
  • ¼öÀÇÇÐ ¿¬±¸¼Ò ¹× Ŭ¸®´Ð
  • POC(Point of Care)/»ç³» ½ÃÇè
  • ¿¬±¸±â°ü ¹× ´ëÇÐ

Á¦10Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ºÐ¼® : ±¹°¡º°
    • ½ÃÀå ¿¹Ãø

Á¦11Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦12Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦13Àå PorterÀÇ Five Forces ºÐ¼®

  • °³¿ä
  • ¹ÙÀ̾îÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • °æÀï Á¤µµ
  • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦14Àå °¡°Ý ºÐ¼®

Á¦15Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • Abbott Laboratories
    • Biomerieux SA
    • Creative Diagnostics
    • HESKA Corporation
    • Innovative Diagnostics
    • IDEXX Laboratories Inc.
    • Neogen Corporation
    • Qiagen N.V.
    • Randox Laboratories Ltd
    • Thermo Fisher Scientific Inc
    • Virbac
LSH 24.09.03

The global veterinary infectious disease diagnostics market size reached US$ 2.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.0 Billion by 2032, exhibiting a growth rate (CAGR) of 7.4% during 2024-2032. Increasing disease prevalence in pets and livestock, rising pet owner awareness, surging technological advancements, the need for accurate diagnostics, adoption of advanced tools, heightened pet health concerns, expanding veterinary infrastructure, government initiatives for zoonotic disease prevention, and enhanced research funding are factors fueling the market growth.

Veterinary Infectious Disease Diagnostics Market Analysis:

Major Market Drivers: Globally, the rising prevalence of zoonotic diseases is significantly increasing the demand for advanced diagnostic solutions, creating a positive outlook for the market. Additionally, increasing government initiatives and funding for animal healthcare is driving the veterinary infectious disease diagnostics market growth. Moreover, the expansion of livestock industry and escalating initiatives by major players for conducting research and development (R&D) activity is propelling the market growth. Additionally, increasing utilization of point-of-care (POC) diagnostics, burgeoning telemedicine usage for veterinary care, and growing consumer awareness about animal welfare and quality standards are further boosting the veterinary infectious disease diagnostics demand.

Key Market Trends: The shifting preference toward molecular diagnostics due to their superior sensitivity and specificity is one of the primary market trends. Moreover, the surging use of clustered regularly interspaced short palindromic repeats (CRISPR) for diagnostics as it can be operated on-site is another factor facilitating the market growth. Additionally, the rising integration of artificial intelligence (AI) and machine learning (ML), especially in diagnostic tools, to produce more accurate results is fostering a positive veterinary infectious disease diagnostics market outlook. In line with this, the increasing demand for companion animals and the gradual shift towards multiplex diagnostic assays that detect a variety of pathogens at the same time are fueling the market growth. Furthermore, the collaborations between veterinary practices and diagnostic laboratories and burgeoning demand for point-of-care (POC) diagnostic solutions are driving the market forward.

Geographical Trends: As per the veterinary infectious disease diagnostics market forecast, North America leads the market due to the presence of advance healthcare infrastructure, along with growing number pet ownership and burgeoning investment in animal health. Moreover, the increasing focus on research and development (R&D) by key players and favorable government policies are supporting the regional market growth. Europe holds a considerable share in the market due to stringent animal health regulations and the presence of a number of key market players. Furthermore, in Asia Pacific, the growing awareness of animal health, the easy availability of infectious diagnostics, and burgeoning government funding in animal health are accelerating the market growth.

Competitive Landscape: Some of the major market players in the veterinary infectious disease diagnostics industry include Abbott Laboratories, Biomerieux SA, Creative Diagnostics, HESKA Corporation, Innovative Diagnostics, IDEXX Laboratories Inc., Neogen Corporation, Qiagen N.V., Randox Laboratories Ltd, Thermo Fisher Scientific Inc, and Virbac, among many others.

Challenges and Opportunities: As per the veterinary infectious disease diagnostics market report, the burgeoning cost of diagnostic tools is one of the primary factors hindering the market growth. Additionally, regulatory obstacles and complex approval processes are creating various challenges for the market players, which is another factor restraining the market growth. However, the market also offers various opportunities, such as the increasing prevalence of infectious diseases in animals and rising pet ownership are establishing a huge demand for advanced diagnostics. Moreover, rapid developments in technology, including the emergence of convenient and easy-to-use diagnostic devices and the growing concern about veterinary health and welfare are factors providing a considerable boost to the veterinary infectious disease diagnostics market revenue.

Veterinary Infectious Disease Diagnostics Market Trends:

Growing Prevalence of Infectious Diseases in Pets and Livestock

Increasing prevalence of infectious diseases among pets and livestock is accelerating the market growth. For instance, feline leukemia virus (FeLV) is one of the most common infectious diseases in cats, affecting between 2-3% of felines in the US and Canada. The risk is further amplified by the surging interactions among pets and humans, which is further escalating the chances of disease transmission. Moreover, the rapid urbanization, changes in animal husbandry practices, and the rising number of diagnosed patients are supporting the market growth. Another factor boosting the veterinary infectious disease diagnostics market value is the burgeoning demand for accurate and timely diagnostics that can assist with efficient control and containment of these diseases.

Increasing Awareness Among Pet Owners

Rising awareness among pet owners about the importance of early disease detection is a crucial factor driving the market growth. With pets being considered integral family members, owners are increasingly prioritizing their health and well-being. This heightened awareness has led to a growing demand for regular health check-ups, preventive measures, and early diagnostic tests. Additionally, the availability of advanced diagnostic tools and technologies has made it easier for pet owners to access high-quality veterinary care, further driving the demand for infectious disease diagnostics.

Technological Advancements

According to the market overview, veterinary infectious disease diagnostics are witnessing considerably demand due to rapid technological advancements. Improvements in diagnostic have greatly improved the efficiency and accuracy of the results, which is further fueling the market growth. Furthermore, the introduction of molecular diagnostic technologies, such as polymerase chain reaction (PCR), designed to improve detection and identification in animal infectious diseases is facilitating the market growth. Apart from this, the incorporation of digital health tools, such as automated analyzers and telemedicine platforms, have simplified the diagnostics process, which is further supporting the market growth.

Veterinary Infectious Disease Diagnostics Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on technology, animal type, infection type and end user.

Breakup by Technology:

Immunodiagnostics

Molecular Diagnostics

Others

Immunodiagnostics accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the technology. This includes immunodiagnostics, molecular diagnostics, and others. According to the report, immunodiagnostics represented the largest segment.

According to the veterinary infectious disease diagnostics market research report, the immunodiagnostics segment holds the largest market share due to the increasing demand for accurate disease detection. Immunodiagnostic tests, including enzyme-linked immunosorbent assays (ELISA) and immunofluorescence assays (IFA), are essential for their ability to specifically detect antibodies or antigens related to infectious diseases. This precision is critical in identifying pathogens and diagnosing diseases at early stages, which is crucial for effective treatment and disease management. As veterinary care becomes more sophisticated, there is a growing expectation for highly reliable diagnostic tools that can provide definitive results quickly. The escalating prevalence of infectious diseases in pets and livestock has heightened the need for such accurate diagnostic solutions.

Breakup by Animal Type:

Companion Animals

Food Producing Animals

Companion animals holds the largest share of the industry

A detailed breakup and analysis of the market based on the animal type have also been provided in the report. This includes companion animals and food producing animals. According to the report, companion animals accounted for the largest market share.

The companion animals segment in the veterinary infectious disease diagnostics market is driven by the focus on pet health and wellness, as well as advancements in diagnostic technology. Furthermore, the increasing prioritization of early disease detection by pet owners, who are more aware of the benefits of proactive health management are driving the market growth. This heightened awareness results in a growing demand for diagnostic services that can identify diseases before they become severe, leading to better health outcomes for pets. The segment is also driven by the availability of advanced diagnostic tools, such as molecular assays and rapid point-of-care tests, which offer accurate and timely results. These innovations enable veterinarians to diagnose and treat infections more effectively, enhancing the overall quality of care for companion animals.

Breakup by Infection Type:

Bacterial Infections

Viral Infections

Parasitic Infections

Others

Bacterial infections represent the leading market segment

The report has provided a detailed breakup and analysis of the market based on the infection type. This includes bacterial infections, viral infections, parasitic infections, and others. According to the report, bacterial infections represented the largest segment.

The bacterial infections segment in the veterinary infectious disease diagnostics market is driven by the burgeoning prevalence of bacterial diseases among animals, which necessitates advanced diagnostic tools for effective management and control. The rising incidence of bacterial infections such as leptospirosis, tuberculosis, and salmonella in both pets and livestock fuels demand for precise diagnostic solutions. The growing awareness of the impact of bacterial diseases on animal health and productivity also drives the need for robust diagnostic methods to ensure early detection and intervention. Additionally, the segment is driven by the shifting focus on food safety, as bacterial infections in livestock can lead to contamination of the food supply, prompting stringent testing and monitoring requirements. The expansion of veterinary healthcare infrastructure and services, particularly in emerging economies, supports the growth of this segment by enhancing access to diagnostic technologies.

Breakup by End User:

Reference Laboratories

Veterinary Laboratories and Clinics

Point of Care/In House Testing

Research Institutes and Universities

Reference laboratories dominates the market

The report has provided a detailed breakup and analysis of the market based on the end user. This includes reference laboratories, veterinary laboratories and clinics, point of care/in house testing, and research institutes and universities. According to the report, reference laboratories represented the largest segment.

The reference laboratories segment in the veterinary infectious disease diagnostics market is driven by the escalating complexity of diagnostic testing requirements. As veterinary diagnostics become more sophisticated, reference laboratories are increasingly relied upon for their advanced capabilities and specialized expertise. The segment is driven by the surging need for accurate and comprehensive diagnostic tests that can differentiate between various pathogens and diseases. This complexity necessitates the use of highly specialized equipment and skilled personnel, which are hallmarks of reference laboratories. Additionally, the segment benefits from the increasing volume of diagnostic samples that require thorough and high-resolution analysis, further underscoring the need for reference laboratories. The rising demand for advanced testing methods, such as molecular diagnostics and genomic analysis, drives the need for specialized reference laboratories capable of conducting these tests with high precision.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest veterinary infectious disease diagnostics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for veterinary infectious disease diagnostics.

The North American veterinary infectious disease diagnostics market is driven by the growing prevalence of infectious diseases among pets and livestock. The rising incidence of diseases such as canine distemper, feline leukemia, and various zoonotic infections in the region underscores the need for effective diagnostic solutions. The regional market is also driven by the burgeoning awareness among pet owners about the importance of early detection and prevention of diseases. Pet owners in North America are more informed and proactive about their pets' health, which fuels demand for advanced diagnostic services. Moreover, the surging technological advancements in veterinary diagnostics, including innovations in molecular biology, rapid testing methods, and automated analyzers, are supporting the market growth. These advancements enhance the accuracy, speed, and efficiency of diagnostic processes. Apart from this, the market is driven by the escalating focus on veterinary research and development (R&D), supported by substantial investments from both private and public sectors.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the veterinary infectious disease diagnostics industry include Abbott Laboratories, Biomerieux SA, Creative Diagnostics, HESKA Corporation, Innovative Diagnostics, IDEXX Laboratories Inc., Neogen Corporation, Qiagen N.V., Randox Laboratories Ltd, Thermo Fisher Scientific Inc, Virbac., etc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Some of the key veterinary infectious disease diagnostics companies in the market are actively engaged in several strategic initiatives to maintain their competitive edge and drive market growth. These companies are focusing on extensive R&D to innovate and enhance diagnostic technologies. By investing heavily in R&D, they aim to introduce advanced diagnostic tools, such as molecular assays and rapid testing devices, that offer greater accuracy and speed in detecting infectious diseases. Collaboration with research institutions and academic organizations is also a priority, facilitating the development of cutting-edge technologies and solutions. Additionally, these players are expanding their product portfolios through strategic acquisitions and partnerships, enabling them to offer a broader range of diagnostic solutions and enter new markets. They are also enhancing their manufacturing capabilities to meet the growing demand for high-quality diagnostic products. Key players are also adopting digital technologies and data analytics to improve diagnostic processes and provide integrated solutions that offer real-time results and predictive insights.

Veterinary Infectious Disease Diagnostics Market News:

In 2023, IDEXX Laboratories introduced a pioneering veterinary diagnostic test to detect kidney injury in cats and dogs. This test, which is the first of its kind, is part of IDEXX's strategy to expand its portfolio with advanced diagnostic solutions that address unmet needs in veterinary care. The new test is expected to significantly improve early diagnosis and treatment outcomes for pets, enhancing their quality of life and extending lifespans.

In 2023, Mars acquired HESKA Corporation to integrate HESKA into Mars Petcare's Science & Diagnostics division, significantly broadening access to advanced diagnostic technologies and accelerating research and development initiatives. This acquisition is expected to enhance HESKA's capabilities in delivering comprehensive diagnostic solutions, including point-of-care diagnostics, telemedicine, and innovative technologies for veterinary professionals globally.

In 2024, Neogen Corporation expanded its product line with the introduction of the SureKill Gel Bait Pro Applicator. This new addition to the SureKill line aims to enhance pest control solutions, particularly in environments where animal health is a priority. The applicator is designed to provide efficient and effective pest control, ensuring safer and healthier conditions for livestock and pets.

Key Questions Answered in This Report:

  • How has the global veterinary infectious disease diagnostics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global veterinary infectious disease diagnostics market?
  • What is the impact of each driver, restraint, and opportunity on the global veterinary infectious disease diagnostics market?
  • What are the key regional markets?
  • Which countries represent the most attractive veterinary infectious disease diagnostics market?
  • What is the breakup of the market based on the technology?
  • Which is the most attractive technology in the veterinary infectious disease diagnostics market?
  • What is the breakup of the market based on the animal type?
  • Which is the most attractive animal type in the veterinary infectious disease diagnostics market?
  • What is the breakup of the market based on the infection type?
  • Which is the most attractive infection type in the veterinary infectious disease diagnostics market?
  • What is the breakup of the market based on the end user?
  • Which is the most attractive end user in the veterinary infectious disease diagnostics market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global veterinary infectious disease diagnostics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Veterinary Infectious Disease Diagnostics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 Immunodiagnostics
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Molecular Diagnostics
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Animal Type

  • 7.1 Companion Animals
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Food Producing Animals
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Infection Type

  • 8.1 Bacterial Infections
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Viral Infections
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Parasitic Infections
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Reference Laboratories
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Veterinary Laboratories and Clinics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Point of Care/In House Testing
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Research Institutes and Universities
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Biomerieux SA
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Creative Diagnostics
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 HESKA Corporation
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Innovative Diagnostics
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 IDEXX Laboratories Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Neogen Corporation
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
    • 15.3.8 Qiagen N.V.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Randox Laboratories Ltd
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
    • 15.3.10 Thermo Fisher Scientific Inc
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Virbac
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦